Search | Clinical Trials Finder

Conditions: Cystic Fibrosis
Interventions: tgAAVCF; Genetic
Lead sponsor: Targeted Genetics Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 11
States / cities: Birmingham, Alabama • Palo Alto, California • San Diego, California + 7 more

Conditions: Solid Tumor
Interventions: PEGPH20; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 3
States / cities: Scottsdale, Arizona • Santa Monica, California • Nashville, Tennessee

Conditions: Acute Respiratory Distress Syndrome, Infections
Interventions: Rhu-pGSN, normal saline; Drug
Lead sponsor: BioAegis Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 11
States / cities: Los Angeles, California • Augusta, Georgia • Chicago, Illinois + 7 more

Conditions: Diabetes Mellitus
Interventions: 30% Regular Insulin Human Neutral and 70%Isophane Insulin, Novolin 70/30; Biological
Lead sponsor: Wockhardt; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Osteoporosis
Interventions: ALX1-11 (drug); Drug
Lead sponsor: Shire; Industry
Eligibility: 45 Years and older · Female only
Enrollment: 1,683 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 84
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 75 more

Conditions: HIV Infections
Interventions: MN rgp120/HIV-1 and GNE8 rgp120/HIV-1, ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2000
U.S. locations: 6
States / cities: Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more

Conditions: Ischemic Stroke
Interventions: Aspirin, tinzaparin sodium, eptifibatide; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 85 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Hemophilia A With Inhibitors, Hemophilia B With Inhibitors
Interventions: Coagulation Factor VIIa (Recombinant); Biological
Lead sponsor: rEVO Biologics; Industry
Eligibility: 12 Years to 75 Years · Male only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 5
States / cities: Los Angeles, California • Sacramento, California • Aurora, Colorado + 2 more

Conditions: Epithelial Ovarian Cancer
Interventions: MUC1 Dendritic Cell Vaccine (Cvac); Biological
Lead sponsor: Prima BioMed Ltd; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 5
States / cities: Greenbrae, California • La Jolla, California • Boca Raton, Florida + 2 more

Conditions: Infertility
Interventions: Follitropin delta, Placebo; Drug · Other
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 34 Years · Female only
Enrollment: 579 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 23
States / cities: Tempe, Arizona • Encino, California • Farmington, Connecticut + 20 more

Conditions: Cytomegalovirus Infections
Interventions: CMV gB vaccine, MF59 adjuvant, Placebo; Biological · Drug
Lead sponsor: Robert Pass, MD; Other
Eligibility: 14 Years to 40 Years · Female only
Enrollment: 464 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2010
U.S. locations: 2
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama

Conditions: Pompe Disease
Interventions: Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase, Rapamycin, saline, Rituxan, Diphenhydramine, Acetaminophen, Lidocaine, LMX 4 Topical Cream; Genetic · Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 50 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: HIV
Interventions: Interleukin-7; Biological
Lead sponsor: Cytheris SA; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 3
States / cities: Miami, Florida • Bethesda, Maryland • Cleveland, Ohio

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSV LID ΔM2-2 1030s vaccine, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 24 Months
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Baltimore, Maryland • Laurel, Maryland

Conditions: Varicella Zoster
Interventions: Recombinant Zoster Vaccine; Biological
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 19 Years to 40 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Chicago, Illinois • Cincinnati, Ohio

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Sargramostim, Ganciclovir; Drug
Lead sponsor: Schering-Plough; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 14
States / cities: Los Angeles, California • San Francisco, California • Sherman Oaks, California + 7 more

Conditions: HIV Infections, Cytopenias
Interventions: Epoetin alfa; Drug
Lead sponsor: Ortho Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Raritan, New Jersey

Conditions: Achromatopsia
Interventions: Prior exposure to AAV-CNGA3 or AAV-CNGB3; Biological
Lead sponsor: MeiraGTx UK II Ltd; Industry
Eligibility: 3 Years to 100 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Growth Hormone Deficiency, Idiopathic Short Stature
Interventions: Somatropin injection; Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 6 Years to 11 Years · Male only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome, Acute Lung Injury, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
Interventions: Atibuclimab, Placebo; Biological · Other
Lead sponsor: Implicit Bioscience; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Staphylococcus Aureus
Interventions: Monovalent rAT, Monovalent rLukS-PV, Bivalent rLukS-PV / rAT, Placebo with adjuvant, Placebo; Biological
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years to 55 Years
Enrollment: 176 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Fort Sam Houston, Texas • Portsmouth, Virginia

Conditions: Advanced Solid Tumors
Interventions: IV Rilvegostomig, Recombinant Human Hyaluronidase (rHu), SC Rilvegostomig, SC rilvegostomig + rHu; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Huntersville, North Carolina • San Antonio, Texas • Fairfax, Virginia

Conditions: Growth Hormone Deficiency (GHD)
Interventions: Saizen®; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: US Medical Information, Massachusetts

Conditions: Haemostasis, Healthy
Interventions: eptacog alfa (activated), clopidogrel, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Neptune City, New Jersey

Search by objective public record fields.

Safety and Efficacy of Recombinant Adeno-Associated Virus Containing the CFTR Gene in the Treatment of Cystic Fibrosis

Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors

Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)

Comparative Wockhardt's Glucose Clamp Study-Human Isophane Susp 30IU/ml/70IU/ml With Novolin70/30, in Healthy Subjects

Open Label Extension Study of PREOS

A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers

Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)

Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors

Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study

Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-1)

Recombinant CMV gB Vaccine in Postpartum Women

Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease

Study on Interleukin-7 (CYT107) in HIV Patients

Evaluating the Infectivity, Safety, and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants and Children 6 to 24 Months of Age

Recombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients

Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis

A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of Subcutaneous Doses of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy

Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3

Skeletal Muscle Effects of GH in Boys

Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients

Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial

A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy

Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study

Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding